keyword
MENU ▼
Read by QxMD icon Read
search

Adalimumab in childrens

keyword
https://www.readbyqxmd.com/read/28337236/adalimumab-for-endoscopic-and-histopathological-mucosal-healing-in-paediatric-patients-with-moderate-to-severe-crohn-s-disease
#1
Edyta Szymanska, Maciej Dadalski, Wieslawa Grajkowska, Sylwia Szymanska, Maciej Pronicki, Jaroslaw Kierkus
INTRODUCTION: Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn's disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much less data for adalimumab (ADA), and none concerning MH on histopathological examination. AIM: To assess the impact of biological therapy with ADA on both endoscopic and histopathological MH in paediatric patients with CD...
2017: Przegla̜d Gastroenterologiczny
https://www.readbyqxmd.com/read/28301428/growth-improvement-with-adalimumab-treatment-in-children-with-moderately-to-severely-active-crohn-s-disease
#2
Thomas D Walters, William A Faubion, Anne M Griffiths, Robert N Baldassano, Johanna Escher, Frank M Ruemmele, Jeffrey S Hyams, Andreas Lazar, Samantha Eichner, Bidan Huang, Yao Li, Roopal B Thakkar
BACKGROUND: Growth failure is common in children with Crohn's disease. The effect of adalimumab (ADA), a fully human antitumor necrosis factor antagonist, on height velocity in pediatric patients with baseline (BL) linear growth impairment in the IMAgINE 1 trial is presented. METHODS: This analysis included female and male patients with growth potential (bone age ≤13 and ≤14 yr, respectively), with BL Pediatric Crohn's disease Activity Index >30, and who failed or were intolerant to conventional therapy...
March 15, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28211161/psoriasis-and-psoriasiform-eruptions-in-pediatric-patients-with-inflammatory-bowel-disease-treated-with-anti-tumor-necrosis-factor-alpha-agents
#3
Joshua B Eickstaedt, Luke Killpack, Jeanne Tung, Dawn Davis, Jennifer L Hand, Megha M Tollefson
BACKGROUND: Anti-tumor necrosis factor alpha (TNF-α) agents are used to treat a variety of autoimmune and inflammatory conditions, including psoriasis. Paradoxically, numerous reports have documented new-onset or exacerbation of psoriasis or psoriasiform skin lesions (PSO) in patients treated with these agents for conditions other than PSO-particularly in adults with inflammatory bowel disease (IBD). Not much is known regarding similar cases in children. METHODS: A retrospective chart review was performed on children younger than 19 years of age with IBD seen at the Mayo Clinic between 2003 and 2015 who developed new-onset or recurrent PSO while undergoing anti-TNF-α therapy...
February 17, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28172915/p352-assessment-of-the-use-of-therapeutic-drug-monitoring-of-adalimumab-during-maintenance-therapy-in-children-with-inflammatory-bowel-disease
#4
M Chavannes, F Gervais, A Verreault, C Deslandres, P Jantchou
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28129288/long-term-efficacy-and-safety-of-adalimumab-in-pediatric-patients-with-crohn-s-disease
#5
William A Faubion, Marla Dubinsky, Frank M Ruemmele, Johanna Escher, Joel Rosh, Jeffrey S Hyams, Samantha Eichner, Yao Li, Nattanan Reilly, Roopal B Thakkar, Anne M Robinson, Andreas Lazar
BACKGROUND: IMAgINE 1 assessed 52-week efficacy and safety of adalimumab in children with moderate to severe Crohn's disease. Long-term efficacy and safety of adalimumab for patients who entered the IMAgINE 2 extension are reported. METHODS: Patients who completed IMAgINE 1 could enroll in IMAgINE 2. Endpoints assessed from weeks 0 to 240 of IMAgINE 2 were Pediatric Crohn's Disease Activity Index remission (Pediatric Crohn's Disease Activity Index ≤ 10) and response (Pediatric Crohn's Disease Activity Index decrease ≥15 from IMAgINE 1 baseline) using observed analysis and hybrid nonresponder imputation (hNRI)...
March 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28119823/pilot-study-of-the-safety-and-effect-of-adalimumab-on-pain-physical-function-and-musculoskeletal-disease-in-mucopolysaccharidosis-types-i-and-ii
#6
Lynda E Polgreen, Alicia Kunin-Batson, Kyle Rudser, Richard K Vehe, Jeanine J Utz, Chester B Whitley, Patricia Dickson
Mucopolysaccharidosis I and II are lysosomal storage disorders that, despite treatment with hematopoietic cell transplantation (HCT) and/or enzyme replacement therapy (ERT), continue to cause significant skeletal abnormalities leading to pain, stiffness, physical dysfunction, and short stature. Tumor necrosis factor - alpha (TNF-α) is elevated in individuals with MPS I and II and associated with pain and physical dysfunction. Therefore, we evaluated the safety and effects of the TNF-α inhibitor adalimumab in patients with MPS I and II in a 32-week, randomized, double blind, placebo-controlled, crossover study of adalimumab at a dose of 20 mg (weight 15-<30 kg) or 40 mg (weight ≥ 30 kg) administered subcutaneously every other week or saline placebo for 16 weeks...
March 2017: Molecular Genetics and Metabolism Reports
https://www.readbyqxmd.com/read/28071837/use-of-tnf-inhibitors-and-ustekinumab-for-psoriasis-during-pregnancy-a-patient-series
#7
Tamara Lund, Simon Francis Thomsen
From 2002 to 2016 a total of seven women with severe refractory psoriasis were exposed to the TNF-inhibitors infliximab and adalimumab or to the IL12/23 inhibitor ustekinumab during one or more pregnancies. Maternal, fetal or teratogenic toxicity were not detected during pregnancy and puerperium. All pregnancies were uneventful and resulted in delivery of 10 healthy children in total, one of the women is due February 2017. Postpartum, five of the women were lactating, but none of the women or newborns developed adverse reactions...
January 10, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/27845027/clinical-effectiveness-and-cost-effectiveness-of-use-of-therapeutic-monitoring-of-tumour-necrosis-factor-alpha-tnf-%C3%AE-inhibitors-lisa-tracker%C3%A2-enzyme-linked-immunosorbent-assay-elisa-kits-tnf-%C3%AE-blocker-elisa-kits-and-promonitor%C3%A2-elisa-kits-versus-standard-care
#8
Karoline Freeman, Martin Connock, Peter Auguste, Sian Taylor-Phillips, Hema Mistry, Deepson Shyangdan, Rachel Court, Ramesh Arasaradnam, Paul Sutcliffe, Aileen Clarke
BACKGROUND AND OBJECTIVES: Systematic reviews and economic modelling of clinical effectiveness and cost-effectiveness of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [using LISA-TRACKER(®) enzyme-linked immunosorbent assay (ELISA) kits (Theradiag, Marne La Vallee, France, or Alpha Laboratories, Heriot, UK), TNF-α-Blocker ELISA kits (Immundiagnostik AG, Bensheim, Germany) and Promonitor(®) ELISA kits (Proteomika, Progenika Biopharma, Bizkaia, Spain)] versus standard care for Crohn's disease (CD)...
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27779782/use-of-tumor-necrosis-factor-alpha-inhibitors-in-children-and-young-adults-with-juvenile-idiopathic-arthritis-or-rheumatoid-arthritis
#9
Wan-Ju Lee, Leslie Briars, Todd A Lee, Gregory S Calip, Katie J Suda, Glen T Schumock
OBJECTIVE: To characterize the use of tumor necrosis factor-α inhibitors (TNFIs) in children with juvenile idiopathic arthritis (JIA) and young adults with rheumatoid arthritis (RA). METHODS: Patients with incident JIA or RA were identified by using the Truven Health MarketScan Commercial Claims and Encounters database from 2009 to 2013. The incident diagnosis was defined as no prior claims with a JIA/RA code and no JIA/RA medications recorded during the previous 6 months...
December 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27749226/update-on-malignancies-in-children-with-juvenile-idiopathic-arthritis-in-the-german-biker-registry
#10
Gerd Horneff, Ariane Klein, Prasad T Oommen, Anton Hospach, Ivan Foeldvari, Isa Feddersen, Kirsten Minden
OBJECTIVES: While tumour necrosis factor (TNF)-α-inhibitor treatment improved outcome of juvenile idiopathic arthritis (JIA) management markedly, concerns have been raised about an association of TNF-α-inhibitor treatment and an increased risk for malignancies especially lymphoma. METHODS: Cases of suspected malignancies documented in the German Biker Registry are reviewed in detail. RESULTS: Until Dec 31, 2015, 3695 JIA patients were prospectively followed with a total of more than 13,198 observation years...
November 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27709443/safety-and-efficacy-of-etanercept-and-adalimumab-in-children-aged-2-to-4%C3%A2-years-with-juvenile-idiopathic-arthritis
#11
D Windschall, G Horneff
The TNF inhibitors etanercept (ETA) and adalimumab (ADA) are approved for treating patients older than 2 years with polyarticular juvenile idiopathic arthritis (JIA). Because long-term experience of treating children younger than 4 years is limited, we evaluated the efficacy and safety of ETA or ADA in patients aged 2-4 years. This prospective, long-term, observational registry study documented baseline demographics, clinical characteristics, disease activity parameters, and safety of patients treated with ETA or ADA...
December 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27636407/biological-therapy-in-pediatric-inflammatory-bowel-disease-a-systematic-review
#12
Domenico Corica, Claudio Romano
The incidence of inflammatory bowel disease (IBD) has increased steadily worldwide, both in adult and in children; approximately 25% of IBD patients are diagnosed before the age of 18. The natural history of IBD is usually more severe in children than in adults, and can be associated with linear growth impairment, delayed puberty onset, reduced bone mass index, malnutrition, and the need for surgery. Biological therapies, especially blocking tumor necrosis factor-α (TNFα), have radically modified the treatment strategies and disease course of IBD in children...
February 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/27600159/autoimmune-sensorineural-hearing-loss-as-presenting-manifestation-of-paediatric-beh%C3%A3-et-disease-responding-to-adalimumab-a-case-report
#13
Manuela Marsili, Valentina Marzetti, Marta Lucantoni, Giuseppe Lapergola, Marco Gattorno, Francesco Chiarelli, Luciana Breda
BACKGROUND: Autoimmune sensorineural hearing loss, also known as autoimmune inner ear disease (AIED) is a rare clinical entity characterized by progressive and bilateral sensorineural hearing loss often accompanied by vestibular symptoms. Diagnosis is essential as a consistent number of patients show a positive response to steroids alone or in association with other immunosuppressive drugs. AIED is defined as primary when the disease is limited to the ear, whereas in up to a third of cases it is associated to other systemic autoimmune diseases such as Behçet disease (BD)...
September 6, 2016: Italian Journal of Pediatrics
https://www.readbyqxmd.com/read/27529048/henoch-sch%C3%A3-nlein-purpura-with-adalimumab-therapy-for-ulcerative-colitis-a-case-report-and-review-of-the-literature
#14
Joseph J LaConti, Jean A Donet, Jeong Hee Cho-Vega, Daniel A Sussman, Dana Ascherman, Amar R Deshpande
Tumor necrosis factor-α (TNFα) inhibitor therapy has signified an important milestone in the fight against many rheumatological disorders and inflammatory bowel disease (IBD). Cutaneous adverse events caused by this class of medications are well known but relatively uncommon. Most reactions are mild and rarely warrant treatment withdrawal. Henoch-Schönlein purpura (HSP) is a disease with cutaneous vasculitis, arthritis, and gastrointestinal and renal involvement that is usually seen in children, though the worst complications are typically seen in adults...
2016: Case Reports in Rheumatology
https://www.readbyqxmd.com/read/27311197/-diagnosis-and-treatment-of-juvenile-idiopathic-arthritis-jia
#15
REVIEW
Syuji Takei
JIA is a chronic disease characterized by joint inflammation of unknown cause which occurs before 16 years of age. It includes 7 forms of clinical subtypes, and it affects about 1 individuals in every 10,000 Japanese children. The treatment strategy and an assessment tool for disease activity (JADAS) to evaluate the treatment efficacy have been established. In addition, induction of biologic agents for JIA patient refractory to conventional therapy resulted in remarkable improvement in the disease course and their joint prognosis...
June 2016: Nihon Rinsho. Japanese Journal of Clinical Medicine
https://www.readbyqxmd.com/read/27195285/recent-advances-in-treatments-of-primary-focal-segmental-glomerulosclerosis-in-children
#16
REVIEW
Kyoung Hee Han, Seong Heon Kim
Focal segmental glomerulosclerosis (FSGS) is a nephrotic syndrome. Up to around 80% of cases of primary FSGS are resistant to steroid treatment. A large proportion of patients with steroid-resistant FSGS progress to end-stage renal disease. The purpose of treatment is to obtain a complete remission of proteinuria, a necessary step that precedes improved renal survival and reduces the risk of progression to chronic kidney disease. When this is not possible, the secondary goal is a partial remission of proteinuria...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27136625/molluscum-contagiosum-of-the-eyelid-case-report-in-a-man-receiving-methotrexate-and-literature-review-of-molluscum-contagiosum-in-patients-who-are-immunosuppressed-secondary-to-methotrexate-or-hiv-infection
#17
Bryce David Beutler, Philip R Cohen
BACKGROUND: Molluscum contagiosum is a benign viral infection of the skin. Lesions typically present as dome-shaped, flesh-colored, umbilicated papules that range in size from 1 to 5 millimeters in diameter. They are usually asymptomatic, but can become tender or pruritic. Children and immunocompromised adults, including individuals being treated with immunosuppressive drugs, are most susceptible to infection. Single or multiple lesions most commonly appear on the extremities, face, genitals, and trunk...
March 16, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/27135404/the-clinical-effectiveness-and-cost-effectiveness-of-abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis-a-systematic-review-and-economic-evaluation
#18
Jonathan Shepherd, Keith Cooper, Petra Harris, Joanna Picot, Micah Rose
BACKGROUND: Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and a limitation of movement caused by inflammation. Subsequent joint damage can lead to disability and growth restriction. Treatment commonly includes disease-modifying antirheumatic drugs (DMARDs), such as methotrexate. Clinical practice now favours newer drugs termed biologic DMARDs where indicated. OBJECTIVE: To assess the clinical effectiveness and cost-effectiveness of four biologic DMARDs [etanercept (Enbrel(®), Pfizer), abatacept (Orencia(®), Bristol-Myers Squibb), adalimumab (Humira(®), AbbVie) and tocilizumab (RoActemra(®), Roche) - with or without methotrexate where indicated] for the treatment of JIA (systemic or oligoarticular JIA are excluded)...
April 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27079596/treatment-of-pediatric-uveitis-with-adalimumab-the-mersi-experience
#19
Claudia Castiblanco, Halea Meese, C Stephen Foster
PURPOSE: To evaluate adalimumab therapy in children with uveitis. METHODS: The electronic health records of pediatric patients diagnosed with uveitis and treated with adalimumab therapy were reviewed retrospectively. Demographic information, site and degree of intraocular inflammation, visual acuity, underlying systemic disorders, duration of therapy, side effects, and ability to obtain steroid-free remission were recorded. RESULTS: A total of 17 patients were included, 16 patients with anterior uveitis and 1 with panuveitis; 14 patients had bilateral disease...
April 2016: Journal of AAPOS: the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus
https://www.readbyqxmd.com/read/27000816/-neurologic-appearence-of-beh%C3%A3-et-disease-in-14-year-old-boy-treated-with-adalimumab-with-good-result
#20
Barbara Iwańczak, Adam Reich, Anna Kofla-Dłubacz, Bernarda Kazanowska, Małgorzata Ruczka
Behçet disease is a multiorgan inflammatory vessel disorder of unknown etiology which only occasionally occurs in children. Here, we demonstrate a 14-year-old boy with Behçet disease diagnosed based on recurrent aphthous stomatitis, acneiform facial lesions, subpreputial erosions and extensive thrombosis involving sigmoid sinus, transverse sinus and right internal cervical vein. Treatment with low molecular weight heparins, systemic corticosteroids, and azathioprine only resulted in partial remission of clinical symptoms...
February 2016: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
keyword
keyword
115701
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"